Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Source :

• Cell cycle (Georgetown, Tex.) [ 1551-4005 ] ; 2010.

Descripteurs français

• KwdFr :
  • 4H-1-Benzopyran-4-ones (usage thérapeutique), Animaux (MeSH), Antibiotiques antinéoplasiques (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Apoptose (MeSH), Butadiènes (usage thérapeutique), Doxorubicine (usage thérapeutique), Interleukine-3 (usage thérapeutique), Leucémie prolymphocytaire (traitement médicamenteux), Lignée cellulaire tumorale (MeSH), Mitogen-Activated Protein Kinase Kinases (antagonistes et inhibiteurs), Mitogen-Activated Protein Kinase Kinases (métabolisme), Morpholines (usage thérapeutique), Nitriles (usage thérapeutique), Paclitaxel (usage thérapeutique), Phase G1 (MeSH), Phosphatidylinositol 3-kinases (métabolisme), Protein-Serine-Threonine Kinases (antagonistes et inhibiteurs), Protein-Serine-Threonine Kinases (métabolisme), Protéines et peptides de signalisation intracellulaire (antagonistes et inhibiteurs), Protéines et peptides de signalisation intracellulaire (métabolisme), Sirolimus (usage thérapeutique), Souris (MeSH), Sérine-thréonine kinases TOR (MeSH), Transduction du signal (effets des médicaments et des substances chimiques).
• MESH :
  • antagonistes et inhibiteurs : Mitogen-Activated Protein Kinase Kinases, Protein-Serine-Threonine Kinases, Protéines et peptides de signalisation intracellulaire.
  • effets des médicaments et des substances chimiques : Transduction du signal.
  • métabolisme : Mitogen-Activated Protein Kinase Kinases, Phosphatidylinositol 3-kinases, Protein-Serine-Threonine Kinases, Protéines et peptides de signalisation intracellulaire.
  • traitement médicamenteux : Leucémie prolymphocytaire.
  • usage thérapeutique : 4H-1-Benzopyran-4-ones, Antibiotiques antinéoplasiques, Antinéoplasiques, Butadiènes, Doxorubicine, Interleukine-3, Morpholines, Nitriles, Paclitaxel, Sirolimus.
  • Animaux, Apoptose, Lignée cellulaire tumorale, Phase G1, Souris, Sérine-thréonine kinases TOR.

English descriptors

• KwdEn :
  • Animals (MeSH), Antibiotics, Antineoplastic (therapeutic use), Antineoplastic Agents (therapeutic use), Apoptosis (MeSH), Butadienes (therapeutic use), Cell Line, Tumor (MeSH), Chromones (therapeutic use), Doxorubicin (therapeutic use), G1 Phase (MeSH), Interleukin-3 (therapeutic use), Intracellular Signaling Peptides and Proteins (antagonists & inhibitors), Intracellular Signaling Peptides and Proteins (metabolism), Leukemia, Prolymphocytic (drug therapy), Mice (MeSH), Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors), Mitogen-Activated Protein Kinase Kinases (metabolism), Morpholines (therapeutic use), Nitriles (therapeutic use), Paclitaxel (therapeutic use), Phosphatidylinositol 3-Kinases (metabolism), Phosphoinositide-3 Kinase Inhibitors (MeSH), Protein-Serine-Threonine Kinases (antagonists & inhibitors), Protein-Serine-Threonine Kinases (metabolism), Signal Transduction (drug effects), Sirolimus (therapeutic use), TOR Serine-Threonine Kinases (MeSH).
• MESH :
  • chemical , antagonists & inhibitors : Intracellular Signaling Peptides and Proteins, Mitogen-Activated Protein Kinase Kinases, Protein-Serine-Threonine Kinases.
  • chemical , metabolism : Intracellular Signaling Peptides and Proteins, Mitogen-Activated Protein Kinase Kinases, Protein-Serine-Threonine Kinases.
  • chemical , therapeutic use : Antibiotics, Antineoplastic, Antineoplastic Agents, Butadienes, Chromones, Doxorubicin, Interleukin-3, Morpholines, Nitriles, Paclitaxel, Sirolimus.
  • drug effects : Signal Transduction.
  • drug therapy : Leukemia, Prolymphocytic.
  • metabolism : Phosphatidylinositol 3-Kinases.
  • Animals, Apoptosis, Cell Line, Tumor, G1 Phase, Mice, Phosphoinositide-3 Kinase Inhibitors, TOR Serine-Threonine Kinases.

Abstract

Affiliations:

• États-Unis
• Caroline du Nord

Links toward previous steps (curation, corpus...)

• to stream Main, to step Corpus: 001413
• to stream Main, to step Curation: 001413

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001437 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001437 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20436269
   |texte=   Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20436269" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

This area was generated with Dilib version V0.6.38. Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020